Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

SK Biopharmaceuticals

KRX: 326030 ↗~$5B MCAP
#Neuroscience#Epilepsy#Sleep Disorders#Oncology

Global CNS-focused biopharmaceutical company developing and commercialising treatments for epilepsy, sleep disorders and oncology, including cenobamate (XCOPRI/Ontozry).

Company Info

Sector:Pharmaceuticals / CNS
Headquarters:Gyeonggi, South Korea
Founded:2011
Website:www.skbp.com/

Upcoming Milestones & Key Dates

2026-Q4
Corporate Milestone

Advancement of partnered preclinical CNS asset licensed in a $315M pact

Clinical Development Pipeline

cenobamate (XCOPRI / Ontozry)

Target: Voltage-gated sodium channel
Focal-onset seizures
Preclinical
Phase 1
Phase 2
Phase 3
Approved

SKL32276

Target: Glucocerebrosidase (GCase) activator
Parkinson's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

carisbamate

Target: Undisclosed
Lennox-Gastaut syndrome
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Careers
Gyeonggi, South Korea
Apply Now →